Clinical trial · Observational
Telomere Biology in Early Adenocarcinoma of the Lung
Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Early adenocarcinoma of the lung has an excellent five-year survival after resection. However, its clinical and radiologic presentation is highly variable. Traditional means for preoperative diagnosis such as Positron Emission Tomography (PET-CT) and trans-thoracic needle biopsy demonstrate unacceptable false positive and negative rates. Telomere biology is activated aberrantly is most lung cancers but has not been studied in early stages to the best of our knowledge. The objective of this study is to evaluate telomere length and activity with suspected early stage adenocarcinoma of the lung.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma, Bronchiolo-Alveolar | Minimally Invasive Lung Adenocarcinoma | ALIAS | 0.90 |
| Adenocarcinoma of the Lung | Lung Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Suspected Adenocarcinoma of the Lung
- description
- Patients with suspected adenocarcinoma of the lung referred for surgical lung biopsy after multi-disciplinary team recommendation.
- label
- Healthy Control
- description
- Age and sex-matched patients with no known lung disease or other chronic inflammatory disease or malignancy
- label
- Age-matched controls with proven solid lung malignancy
- description
- Patients with biopsy-proven advanced solid malignancy of the lung
Primary outcomes (1)
- measure
- Telomere Capture Percentage
- timeFrame
- one-time peripheral blood sample
- description
- According to our previous experience with telomore biology in different disease states, we estimate a standard deviation (SD) of 1.3 of telomere capture (%) for the controls (healthy patients without known lung disease) and a SD of 2.4 (TC%) for biopsy-proven adenocarcinoma of the lung. For a clinically significance of at least 2%, we estimate a sample size of at least 16 patients with biopsy-proven disease to detect a statistically significant of 5% with a power of 80% (calculated by the independent t-test).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: Patients referred by a multi-disciplinary team meeting recommendation for surgical lung biopsy due to suspected adenocarcinoma of the lung and agree to a one-time peripheral blood sample for telomere analysis as described. Exclusion Criteria: Patients whom were not evaluated by the multi-disciplinary team discussion prior to referral for surgical lung biopsy. Patients with other chronic inflammatory disease requiring immunosuppressive therapy or known extra-pulmonary malignancy.
References
Publications (0)
Data not yet available